This synergistic effect was linked to the suppression of Wnt/β-catenin signaling, suggesting that the EZH2–PPAR axis could serve as a potential therapeutic target in pancreatic cancer (Hu et al. 2021). The gene discussed is PPARA; the disease is pancreatic neoplasm.